Aclidinium: A guide to its use in chronic obstructive pulmonary disease in the EU

被引：0
|
作者：
Scott L.J. [1 ]
Lyseng-Williamson K.A. [1 ]
Frampton J.E. [1 ]
机构：
[1] Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland
来源：
Drugs & Therapy Perspectives | 2013年 / 29卷 / 2期
关键词：
Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Formoterol; Tiotropium; Major Adverse Cardiovascular Event;
D O I：
10.1007/s40267-013-0014-3
中图分类号：
学科分类号：
摘要：
Inhaled aclidinium (Eklira® Genuair® [EU]; Bretaris® Genuair® [EU]; Tudorza™ Pressair™ [US]) is a long-acting antimuscarinic agent. In the EU, it is indicated as maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD). Aclidinium provides improvements in lung function, dyspnoea and disease-specific health status in patients with COPD, and is generally well tolerated. © 2013 Springer International Publishing Switzerland.
引用
收藏
页码：34 / 39
页数：5
相关论文
共 50 条
12345